Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.
about
Eluxadoline: First Global Approval.Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.Renal Drug Transporters and Drug Interactions.Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea.Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome.Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.
P2860
Q38543345-1773E8B8-1472-4B32-8ECB-A489AE1539DCQ38772302-B25F2228-8CC9-4CA9-A0F1-53F85A197F17Q38856699-02966148-FDC3-431E-8F76-D8700F8FFBDBQ39140289-3DD8239A-2A48-466D-B98B-24809E80567FQ39298126-B059676D-50A4-4770-ACB4-0A27BAADED6EQ39372153-FBC773E6-B540-44E1-867B-1159023CCCA7Q41064891-6006DD68-8C38-49A4-AC54-535116C096F2Q42184351-A3AC2BA6-9821-48A1-BC66-47A53E11EA43Q42370590-27E4317E-8FE3-4DEC-B260-C99A88F031EDQ43062026-D7233F8F-E43F-4CED-84A6-49C38E9AECDEQ46591319-BBAAE796-0C47-422D-BE1A-FD0F6AA507ECQ47768109-C9E76C91-7849-49A8-A104-60E413CA612FQ50308630-AACDA03B-DC3F-422A-89AF-672D19E94BC9
P2860
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@ast
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@en
type
label
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@ast
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@en
prefLabel
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@ast
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@en
P2093
P2860
P356
P1476
Effect of uptake transporters ...... armacokinetics of eluxadoline.
@en
P2093
Gail McIntyre
J Michael Davenport
Jürgen Venitz
Laura Bonifacio
Paul Covington
P2860
P304
P356
10.1002/JCPH.442
P577
2015-01-14T00:00:00Z